Jeffrey S. Miller, M.D.
Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.
Cassian Yee, M.D.
Cassian Yee, M.D., Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research at the University of Texas MD Anderson Cancer Center and a Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer. Dr. Yee previously held the position of Professor in Division of Oncology at the University of Washington, and was a Member in the Department of Immunology, Clinical Research Division of the Fred Hutchinson Cancer Research Center. Dr. Yee received his medical degree from the University of Manitoba in Canada, and trained as a research fellow at the Ontario Cancer Institute in Toronto before continuing his medical residency at Stanford University. Dr. Yee completed his fellowship in medical oncology, and postdoctoral research studies at the University of Washington and the Fred Hutchinson Cancer Research Center. Dr. Yee is a recipient of the Cancer Research Institute Investigator Award, and the Damon Runyon Walter Winchell Clinical Investigator Award. Dr. Yee is also a Burroughs Wellcome Scientist in Translational Research, and has been elected a member of the American Society for Clinical Investigation.
Pierre N. Tariot, M.D.
Dr. Tariot is a Phi Beta Kappa graduate of Amherst College who attended the University of Rochester School of Medicine. He completed residencies in Internal Medicine and Psychiatry at the University of Wisconsin in Madison, Wisconsin, and is Board Certified in both specialties, with added qualifications in geriatrics. He served as a Fellow at the Intramural Research Program of the National Institute of Mental Health. In 1986, he joined the faculty of the University of Rochester Medical Center, achieving the rank of Professor of Psychiatry, Medicine, Neurology, and Aging and Developmental Biology; while there, he served as Director of the Memory Disorders Clinic, Director of Psychiatry at Monroe Community Hospital, and Director of the University of Rochester component of the NIA-funded Alzheimer's Disease Cooperative Study. Since 2006, he has been at the Banner Alzheimer's Institute, where he serves as Director. Dr. Tariot has investigated, and lectured extensively on, multiple aspects of diagnosis, therapy and prevention of Alzheimer's disease, and has published over 250 papers on these topics. He has served as author for several studies that have led to FDA approval of treatments for Alzheimer's disease.
Lisa A. Haile, Ph.D.
Dr. Lisa A. Haile, Ph.D. currently serves as Co-Chair, Global Life Sciences Sector at DLA Piper. Dr. Haile has special technical expertise in molecular biology and immunology . She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management and value creation. Dr. Haile is a member of DLA Piper's Executive Committee.
Dr. Haile's experience includes US and international patent preparation and prosecution as well as IP reviews for investors relating to technologies including novel genetically altered organisms, antisense, RNA and siRNA molecules, peptides, proteins, DNA, antibodies, vaccines, diagnostics and therapeutics.
Daniel Vallera, Ph.D.
Dr. Vallera received his Ph.D. in Microbiology (Immunology) from the Ohio State University, Columbus, Ohio. He conducted post-doctoral training in the laboratory of Dr. John H. Kersey, Dept. of Laboratory Medicine/Pathology at the University of Minnesota. He joined the Masonic Cancer Center in 1984 where he conducts research on the development of new recombinant biological anti-cancer agents.
Roger Porter, M.D.
Dr. Roger Porter, M.D., serves as Chief Scientific Officer of the Epilepsy Therapy Project. Dr. Porter held senior management positions and directed worldwide clinical research at Wyeth. Dr. Porter spent 20 years at the National Institutes of Health (NIH), in leadership positions including Chief of the Epilepsy Branch, Chief of the Medical Neurology Branch and Deputy Director of the National Institute of Neurological Disorders and Stroke. He serves as Member of the Scientific Advisory Board at Insero Health, Inc. His other leadership positions include Chairman of the White House Committee on Brain and Behavioral Sciences; President, American Epilepsy Society; and Secretary-General of the International League Against Epilepsy. He served as President of the American Society for Experimental NeuroTherapeutics and a Fellow of the American Academy of Neurology.